HIV infection is caused by the transfer of one or both of the two known viruses that are responsible for causing the life-threatening infection, which eventually progresses into AIDS, or acquired immunodeficiency syndrome. These viruses both fall under the species of Lentivirus, which are most frequently transmitted between people through the following modes of transfer:
- Pre-cum, also known as pre-seminal fluid
- Rectal and vaginal fluids
Although some people swear that the viruses responsible for causing human immunodeficiency virus infection cannot be transferred to one another through skin-to-skin contact, such as by shaking hands or hugging, it’s important to know that there’s no reason to unnecessarily avoid contact with active carrier of either of the two types of Lentivirus.
However, it is a good idea to watch out for open cuts, wounds, sores, and the like, as blood could easily leak out of these relatively transient portals to the human body’s bloodstream. You should also keep an eye peeled for these sores on your own body. Even if they’re covered with gauze, athletic tape, adhesive bandages (e.g. Band-Aid), or other protective artificial layers, they could very well field bodily fluids through which the HIV infection can be transmitted.
In 2012, the United States Food and Drug Administration, or FDA, approved Truvada, a patented, brand-name form of the emtricitabine-tenofovir combination tablets that are used to both prevent and treat HIV and AIDS.
Truvada doesn’t actually entirely eliminate the viruses responsible for HIV and AIDS from carriers of the responsible Lentivirus varieties, though they are killed off over time so that these patients carry very low human immunodeficiency virus counts, make it difficult to transmit the disease between humans.
Fortunately for Society, Especially Carriers of HIV or People Who Are at High Risk for Receiving HIV Infection, a New Form of PrEP Has Hit the Market
Truvada, the only existing approved drug for preventing and treating HIV, contains emtricitabine and tenofovir disoproxil fumarate in the amounts of 200 and 300 milligrams, respectively.
The FDA recently approved Descovy, a combination tablet including 200 milligrams of emtricitabine and 25 milligrams of tenofovir alafenamide. This development was announced yesterday, Friday, Oct. 4, 2019.
Although it’s unarguably great for the available government-approved selection of HIV-treating and -preventing drugs to widen, the only drawback of Descovy is that it won’t work as advertised in those who have heterosexual, vaginal-and-penile penetrative sex.